Microbial metabolism of dietary components to bioactive metabolites: opportunities for new therapeutic interventions.

Zhang LS, Davies SS. · 2016

Read Microbial metabolism of dietary components to bioactive metabolites: opportunities for new therapeutic interventions. by Zhang LS, Davies SS. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4840492.txt.

Introduction

Linda S. Zhang and Sean S. Davies reviewed how gut microbes turn food parts into active compounds, in Genome Medicine in 2016. Studies that compare sick and healthy people often find microbe-made compounds among the most changed. The review gathers the most striking cases, where a food-derived product shapes gut health, immunity, blood vessels, energy use, or behavior.

Cases covered include short-chain fatty acids, a compound called trimethylamine N-oxide, products of the amino acids tryptophan and tyrosine, and oxidized fats. Each case suggests a treatment path: change the microbes, or block or boost the compound itself. The authors note that such steps need care, since the same compound can help one system and harm another.

Catalog record

CREATORZhang LS, Davies SS.
YEAR2016
COLLECTIONPAPERS
FORMATTXT
FILE SIZE92 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4840492

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Microbial metabolism of dietary components to bioactive metabolites: opportunities for new therapeutic interventions By Linda S. Zhang, Sean S. Davies Published in: Genome Medicine DOI: 10.1186/s13073-016-0296-x ABSTRACT Mass spectrometry- and nuclear magnetic resonance-based metabolomic studies comparing diseased versus healthy individuals have shown that microbial metabolites are often the compounds most markedly altered in the disease state. Recent studies suggest that several of these metabolites that derive from microbial transformation of dietary components have significant effects on physiological processes such as gut and immune homeostasis, energy metabolism, vascular function, and neurological behavior. Here, we review several of the most intriguing diet-dependent metabolites that may impact host physiology and may therefore be appropriate targets for therapeutic interventions, such as short-chain fatty acids, trimethylamine N-oxide, tryptophan and tyrosine derivatives, and oxidized fatty acids. Such interventions will require modulating either bacterial species or the bacterial biosynthetic enzymes required to produce these metabolites, so we briefly describe the current understanding of the bacterial and enzymatic pathways involved in their biosynthesis and summarize their molecular mechanisms of action. We then discuss in more detail the impact of these metabolites on health and disease, and review current strategies to modulate levels of these metabolites to promote human health. We also suggest future studies that are needed to realize the full therapeutic potential of targeting the gut microbiota. ALTERATIONS IN MICROBIAL TRANSFORMATION OF DIETARY COMPONENTS ASSOCIATE WITH DISEASE The symbiotic relationship between mammals and the trillions of microbial cells that reside in their gastrointestinal tracts relies on a complex molecular dialogue, with microbial metabolites acting as major mediators of this dialogue. Essential roles for several microbial metabolic pathways in host physiology have been long established, including in the production of vitamin K, the production of water-soluble B vitamins including biotin, folates, nicotinic acid, pyridoxine, riboflavin, cobalamin and panthotenic acid, the degradation of dietary oxalates, and modification of bile salts (reviewed in [1, 2]). However, intense interest in the gut microbiota over the past decade has led to the discovery of many new areas where bacterial transformation of dietary components may play critical roles in host health and disease. This increased understanding of diet–microbiota–host interactions suggests significant opportunities to create new therapeutic approaches, including selectively altering the microbial production of molecules to promote human health and prevent disease [3]. Elucidating target microbial metabolites that modulate host physiology requires identifying the major metabolites (and their downstream co-metabolites formed by the phase I/II xenobiotic metabolizing enzymes of their host) that differ between healthy and diseased individuals, and assessing the biological activities of these metabolites. A series of landmark metabolomics studies over the past decade have significantly advanced our understanding by using mass spectrometry (MS) or nuclear magnetic resonance (NMR) analysis to identify potentially important microbial metabolites that derive from the gut microbes [4–10], that are enriched or depleted in diseased individuals [11–30], or that can be used to predict physiological response to foods or other interventions [31, 32] (Table 1). These studies have identified a number of metabolites that may play important roles in human health and disease, including short-chain fatty acids (SCFAs) and long-chain fatty acid metabolites such as conjugated linoleic acid (CLA) and 10-hydroxy-cis-12-octadecenoate (HYA); trimethylamine (TMA) and trimethylamine N-oxide (TMAO); tryptophan metabolites such as indole, indole-3-propionate (IPA) and indoxyl-sulfate (IndsS); and tyrosine and phenylalanine metabolites such as hippuric acid, phenylacetylglycine, phenyl sulfate, para-cresyl sulfate (PCS), phenylpropionylglycine, cinnamoylglycine and equol sulfate. Many of the metabolites identified by these studies result from the transformation of specific dietary components by select species of microbes that express the necessary enzymes to act on these components. Thus, the variable presence of microbes utilizing these diet-dependent metabolic pathways may be key to understanding the variable host response to specific dietary components and susceptibility to disease [32].Table 1Key microbial metabolomic studies of the past decadeStudies identifying major gut microbial metabolitesAim of studyPopulationResultsReferenceIdentify metabolites modulated by gut microbiota in various tissue and fluidsConventional versus germ-free C3H/HeJ mice•Higher bile acid levels in gut of germ-free mice.•Higher phosphocholine and glycine in liver of germ-free mice.•Hippurate and 5-aminovalerate reduced in germ-free animals.•Higher levels of betaine, choline and myo-inositol in kidney of germ-free mice.[4]Determine effect of antibiotic treatment on metabolomeNormal versus vancomycin-treated female NMRI mice•Vancomycin reduced urinary levels of hippurate, phenylacetylglycine, taurine, TMA and TMAO, and increased urinary levels of α-ketoisovalerate, n-butyrate, creatinine, guanidoacetic acid and glycine.•Vancomycin reduced fecal levels of uracil, amino acids, SCFAs and urinary phenylacetylglycine and hippurate.[5]Identify metabolites derived from the gut microbiotaConventional versus germ-free Swiss Webster mice•Metabolites highly enriched or only present in conventional mice include indole derivatives (such as indoxyl sulfate and IPA), phenyl/benzoate derivatives. (hippurate, p-cresol), and conjugated fatty acids.[6]Identify serum metabolites derived from gut microbiotaConventional versus germ-free Swiss Webster mice•Increased serum metabolites related to energy metabolism (pyruvic acid, citric acid, fumaric acid, malic acid) in conventional compared to germ-free mice.[7]Determine effect of antibiotics on metabolite productionNormal versus penicillin- and streptomycin-treated Han–Wistar rats•Antibiotics reduced urinary excretions of hippurate, phenylpropionic acid, phenylacetylglycine and indoxyl-sulfate, and elevated urinary excretions of taurine, glycine, citrate, 2-oxoglutarate and fumarate.•Antibiotics reduced fecal SCFA.[8]Identify fecal and urinary metabolites derived from the gut microbiotaNormal versus imipenem/cilastatin Wistar rats•Antibiotic treatment altered 202 urinary and 223 fecal metabolites.•Major classes reduced by antibiotics include SCFAs, phenyl/benzoates (for example, p-hydroxyphenylacetate, m-hydroxyphenylacetate, hydroxycinnamic acid, phynylvalerate, p-aminobenzoate and hippurate), and indole-containing substances (indoxyl sulfate, indole-acetate, indole-carboxylate and indole-acetaldehyde), and urobilin. Antibiotic treatment increased tryptophan and tryptamine in feces.[9]Compare metabolomes of human versus humanized and conventionally raised mice.Germ-free versus humanized versus conventional Swiss Webstermice•Metabolome of humanized mice was more similar to metabolome of human donors than to metabolome of conventional mice, with more differences in feces than urine.•Humanized mice had higher fecal levels of tryptamine and indoxyl glucuronide, and lower levels of trisaccharide, creatine and creatinine than conventional mice.[10]Studies examining microbial metabolites enriched or depleted in disease statesDiseaseAim of studyPopulationResultsReferenceMetabolic disorders and CVDIdentify metabolites associated with fatty liver diseaseDisease-susceptible (129S6) versus disease-resistant (BALBc) mice•Increased urinary dimethylamine, TMA, TMAO, formate and hippurate in 129S6 mice on HFD.•Decreased plasma phosphatidylcholine seen in 129S6 mice likely due to microbial conversion to TMA.[11]Identify metabolites associated with obesityFecal transplantation from ob/ob, ob/+, +/+ C57BL/J mice to germ-free mice•Recipients of fecal transplant reciprocate phenotype of donor. Cecal levels of acetate and butyrate increased in obese mice.[12]Identify urinary metabolites associated with obesityLean versus obese Zucker rat•Obese mice have higher urinary creatinine, TMAO, hippurate and acetate.[13]Identify metabolites associated with obesityHealthy versus obese insulin-resistant male humans•Increased microbiota-derived hippurate acid, trigonelline, 2-hydroxyisobutyrate and xanthine was seen in the obese microbiota[14]Identify metabolites that predict CVDHuman subjects with CVD•Three metabolites of dietary phosphatidylcholine (choline, TMAO, betaine) predict risk for CVD.•Studies in mice confirmed critical role for dietary choline and gut flora in TMAO production and CVD.[15]Identify metabolites elevated in mice highly susceptible to diet-induced obesity.C57J versus C57N mice•C57N more susceptible to diet-induced obesity than C57J.•In cecum, C57N have decreased taurine-conjugated bile acids, bile acid sulfates, enterolactone and enterodiol; altered arachidonate metabolites and increased urobilins.•In liver, C57N have increased taurine-conjugated bile acids, fatty acids and urobilins.[16]Identify urinary metabolite associated with human adiposityHuman subjects from INTERMAP study (n = 2324)•Urinary metabolites associated with increased BMI included N-acetyl neuraminate, TMA, PCS, succinate, citrate ethanolamine.[17]Determine effects of bariatric surgery on metabolomeSeverely obese human subjects undergoing bariatric surgery•Bariatric surgery reversed most metabolites associated with obesity such

Read the complete text